Sensitivity and specificity of the ECAS in Parkinson’s disease and Progressive Supranuclear Palsy

Jennifer A. Foley, Elaine H. Niven, Andrew Paget, Kailash P Bhatia, Simon F. Farmer, Paul R. Jarman, Patricia Limousin, Thomas T. Warner, Huw R. Morris, Thomas Bak, Sharon Abrahams, Lisa Cipolotti

Research output: Contribution to journalArticlepeer-review

Abstract / Description of output

Disentangling Parkinson’s disease (PD) and Progressive Supranuclear Palsy (PSP) may be a diagnostic challenge. Cognitive signs may be useful, but existing screens are often insufficiently sensitive or unsuitable for assessing people with motor disorders. We investigated whether the newly-developed ECAS, designed to be used with people with even severe motor disability, was sensitive to the cognitive impairment seen in PD and PSP, and able to distinguish between these two disorders. 30 patients with PD, 11 patients with PSP and 40 healthy controls were assessed using the ECAS, as well as an extensive neuropsychological assessment. The ECAS detected cognitive impairment in 30 % of the PD patients, all of whom fulfilled diagnostic criteria for mild cognitive impairment. The ECAS was also able to detect cognitive impairment in PSP, with 81.8 % of patients performing in the impaired range. ECAS total score distinguished between PSP and healthy controls with high sensitivity (91.0) and specificity (86.8). Importantly, the ECAS was also able to distinguish between the two syndromes, with the measures of verbal fluency offering high sensitivity (82.0) and specificity (80.0). In sum, the ECAS is a quick, simple and inexpensive test that can be used to support the differential diagnosis of PSP.
Original languageEnglish
Article number2426012
Number of pages8
JournalParkinson's Disease
Publication statusPublished - 9 May 2018


Dive into the research topics of 'Sensitivity and specificity of the ECAS in Parkinson’s disease and Progressive Supranuclear Palsy'. Together they form a unique fingerprint.

Cite this